BioSpace News Archive

BeiGene, Ltd., a global oncology company, announced it will share new data from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain, June 13-16, 2024.

Gossamer Bio, Inc. will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

Pulse Biosciences, Inc., a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, announced enhancements to its executive leadership team to support its next pivotal phase of growth.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, announced its cash position as of March 31, 2024 and revenues for the first three months of 2024.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today reported its first quarter 2024 operating and financial results and reviewed recent business highlights.

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the first quarter of 2024 and provided a corporate update.

Shattuck Labs, Inc., a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, announced the presentation of additional data from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in frontline HR-MDS and TP53m AML patients.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the first quarter ended March 31, 2024, and recent corporate developments.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, reported its first-quarter 2024 financial results.